Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
10.12779/dnd.2024.23.4.165
- Author:
Kee Hyung PARK
1
;
Geon Ha KIM
;
Chi-Hun KIM
;
Seong-Ho KOH
;
So Young MOON
;
Young Ho PARK
;
Sang Won SEO
;
Bora YOON
;
Jae-Sung LIM
;
Byeong C. KIM
;
Hee-Jin KIM
;
Hae Ri NA
;
YongSoo SHIM
;
YoungSoon YANG
;
Chan-Nyoung LEE
;
Hak Young RHEE
;
San JUNG
;
Jee Hyang JEONG
;
Hojin CHOI
;
Dong Won YANG
;
Seong Hye CHOI
Author Information
1. Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
- Publication Type:Review Article
- From:Dementia and Neurocognitive Disorders
2024;23(4):165-187
- CountryRepublic of Korea
- Language:English
-
Abstract:
Lecanemab (product name Leqembi ® ) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations,administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.
